Data from the AFIRE study showed that oral anticoagulant monotherapy with rivaroxaban was superior to combination therapy with regard to both safety and efficacy. These findings support guideline recommendation of oral anticoagulant monotherapy for this population.
The Japanese AFIRE study researched whether rivaroxaban monotherapy is non-inferior to combination therapy (rivaroxaban + antiplatelet agent) in atrial fibrillation (AF) patients with stable coronary artery disease (CAD) who did not require percutaneous coronary intervention (PCI) or more than 1 year after PCI or coronary artery bypass grafting (CABG) . A total of 2,236 patients were randomised to either rivaroxaban monotherapy or combination therapy (rivaroxaban + antiplatelet agent). The primary efficacy endpoint was stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularisation, and all-cause mortality. The primary safety endpoint was major bleeding.
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Catheter ablation plays key role in 2019 ESC Guidelines on tachycardia Next Article
Genetic testing non-inferior to standard drug treatment with regard to thrombotic events »
Table of Contents: ESC 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.